The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide
- PMID: 27943236
- DOI: 10.1111/bjd.15233
The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide
Abstract
Hidradenitis suppurativa (HS) is a cutaneous disease associated with systemic inflammation, obesity and metabolic syndrome. Effective treatment options are limited. The antidiabetic agents, incretins, have been used successfully to treat psoriasis - a disease also associated with metabolic syndrome. We report the use of liraglutide, a glucagon-like peptide-1 agonist, in a patient with HS, leading to subsequent weight loss and improvement in disease control. To our knowledge, this is the first report of liraglutide used in the treatment of HS.
© 2016 British Association of Dermatologists.
Comment in
-
Glucagon-like peptide-1 agonists for treatment of hidradenitis suppurativa.Br J Dermatol. 2017 Sep;177(3):625-627. doi: 10.1111/bjd.15742. Br J Dermatol. 2017. PMID: 28940285 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
